



# THE OBESITY SOCIETY

---

The Late-Breaking Clinical Trials Session presents innovative research on the latest breakthroughs in clinical science. These sessions provide notable exposure and recognition for studies likely to have a significant impact on clinical practice. Abstracts submitted via the online application process for late-breaking abstracts are expected to contain study design and the major trial results. Data submitted for the Late-Breaking Clinical Trials Session will be treated as strictly confidential by The Obesity Society and its individual reviewers.

## **Embargo Policies**

Clinical trial results are embargoed for the time of an Obesity Society-sponsored news media activity or the date and time of presentation, whichever comes first. Clinical trial sponsors must comply with embargo guidelines established by The Obesity Society. It is essential to recognize that presentations at unofficial satellite meetings or unofficial press conferences before the scheduled session are not allowed. The pre-conference Pharmacotherapy Update is an official Obesity Society event and this embargo policy does not apply to that session, although it is expected that late-breaking trial results will not be reported in detail during the event. The embargo policy will be strictly enforced.

*Note exception:* Industry announcements required by the Security Exchange Commission are allowed and will not be considered an embargo break; however, no trial results or data may be revealed or implied.

## **Investigator Meetings**

The only exceptions to the above-mentioned embargo policy are closed investigator meetings for participants in the trial. Graphics (slide or print) that contain key trial results should be kept to a minimum and not distributed. Media or other outside parties may not be invited to these events.

## **Simultaneous Journal Publication of Clinical Trials**

Simultaneous publication of late-breaking clinical trials is acceptable and encouraged as long as the embargo policies of The Obesity Society and the involved journals are coordinated. If a clinical trial has been submitted to and accepted for publication, the presenter is responsible for ensuring that the journal editor respects The Obesity Society publication embargo policy. Publication of a clinical trial either in print or on a journal website prior to presentation at a Scientific Session will necessitate withdrawal of the trial from the program.